Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Int. J. Mol. Sci. 2012, 13(9), 12000-12016; doi:10.3390/ijms130912000
Article

Anti-Epidermal Growth Factor Receptor (EGFR) Antibodies Overcome Resistance of Ovarian Cancer Cells to Targeted Therapy and Natural Cytotoxicity

1,2
, 2
, 1
, 3
 and 1,*
Received: 16 July 2012; in revised form: 5 September 2012 / Accepted: 11 September 2012 / Published: 20 September 2012
(This article belongs to the Special Issue Advances in Molecular Oncology)
View Full-Text   |   Download PDF [493 KB, uploaded 19 June 2014]
Abstract: The poor outcome of advanced ovarian cancer under conventional therapy stimulated the exploration of new strategies to improve therapeutic efficacy. In our preclinical in vitro study we investigated a combination of targeted therapy and immunotherapy. Combination treatment with the anti-EGFR-antibody Cetuximab, related tyrosine kinase inhibitors (TKI) and cytolytic NK cells was tested against different ovarian cancer cell lines and primary tumour cells cultured from patient ascites. We found that selected ovarian cancer cells were susceptible to cetuximab and anti-EGFR-TKI-treatment, while the majority of cell lines were resistant to single or combination treatment with both substances. In addition, most ovarian cancer cells displayed low susceptibility to natural cytotoxicity of unstimulated NK cells. Notably, NK cytotoxicity against resistant ovarian cancer cells could be effectively enhanced by addition of Cetuximab mediating antibody-dependent cellular cytotoxicity (ADCC). Neither natural cytotoxicity nor ADCC of NK cells were negatively affected by the presence of TKIs. ADCC could be further increased when NK cells were pre-stimulated with monocytes and the immunostimulatory mycobacterial protein PstS-1. Our data suggest that targeted antibody therapy could be beneficial even against resistant tumour cells by augmenting supplementary cytolytic NK functions. Future studies should evaluate the combination of targeted therapy and immunotherapeutic approaches in patients with advanced ovarian cancer being resistant to standard treatment.
Keywords: ovarian cancer; NK cell; cetuximab; EGFR; PstS-1; antibody-dependent cellular cytotoxicity ovarian cancer; NK cell; cetuximab; EGFR; PstS-1; antibody-dependent cellular cytotoxicity
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Gottschalk, N.; Kimmig, R.; Lang, S.; Singh, M.; Brandau, S. Anti-Epidermal Growth Factor Receptor (EGFR) Antibodies Overcome Resistance of Ovarian Cancer Cells to Targeted Therapy and Natural Cytotoxicity. Int. J. Mol. Sci. 2012, 13, 12000-12016.

AMA Style

Gottschalk N, Kimmig R, Lang S, Singh M, Brandau S. Anti-Epidermal Growth Factor Receptor (EGFR) Antibodies Overcome Resistance of Ovarian Cancer Cells to Targeted Therapy and Natural Cytotoxicity. International Journal of Molecular Sciences. 2012; 13(9):12000-12016.

Chicago/Turabian Style

Gottschalk, Nina; Kimmig, Rainer; Lang, Stephan; Singh, Mahavir; Brandau, Sven. 2012. "Anti-Epidermal Growth Factor Receptor (EGFR) Antibodies Overcome Resistance of Ovarian Cancer Cells to Targeted Therapy and Natural Cytotoxicity." Int. J. Mol. Sci. 13, no. 9: 12000-12016.



Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert